During the past two decades we have seen a phenomenal evolution of bispecific antibodies
for therapeutic applications. The 'zoo'of bispecific antibodies is populated by many different …

Safety and efficacy constitute the major criteria governing regulatory approval of any new
drug. The best method to maximize safety and efficacy is to deliver a proven therapeutic …

Therapeutic gene silencing promises significant progress in pharmacotherapy, including
considerable expansion of the druggable target space and the possibility for treating orphan …

Protein-based therapeutics have been revolutionizing the oncology space since they first
appeared in the clinic two decades ago. Unlike traditional small-molecule …

Antibodies have proved to be a valuable mode of therapy for numerous diseases, mainly
owing to their high target binding affinity and specificity. Unfortunately, antibodies are also …

Integrins are transmembrane receptors that are central to the biology of many human
pathologies. Classically mediating cell-extracellular matrix and cell-cell interaction, and with …

Highlights•ADC represents a new class of targeted anticancer therapeutics.•Elucidates
selection criteria for tumor specific antigen and ADC development.•Smart linkers and fixed …

Peptide aptamers are small combinatorial proteins that are selected to bind to specific sites
on their target molecules. Peptide aptamers consist of short, 5-20 amino acid residues long …

Targeted delivery of chemotherapeutics aims to increase efficacy and lower toxicity by
concentrating drugs at the site-of-action, a method embodied by the seven current FDA …

The emergence of novel binding proteins or antibody mimetics capable of binding to ligand
analytes in a manner analogous to that of the antigen–antibody interaction has spurred …